NMN (nicotinamide mononucleotide) is not banned. The FDA effectively blocked it from being sold as a dietary supplement in late 2022, but reversed that decision in 2025 after a lawsuit and citizen petition from the Natural Products Association. NMN is once again a legal dietary supplement in the United States.
The story between those two dates, though, matters if you’re buying NMN or trying to understand why it disappeared from Amazon for a while. Here’s what happened and where things stand now.
The 2022 FDA Ruling That Pulled NMN From Shelves
In November 2022, the FDA told two ingredient suppliers, SyncoZymes and Inner Mongolia Kingdomway Pharmaceutical, that NMN could not be sold as a dietary ingredient. The reason had nothing to do with safety concerns. It came down to a legal technicality in federal food and drug law.
Under the Federal Food, Drug, and Cosmetic Act, a substance that’s been “authorized for investigation as a new drug” can’t also be sold as a dietary supplement, unless it was already on the market as a supplement before the drug investigation began. This provision exists to protect pharmaceutical companies’ incentive to invest in clinical trials. If a company spends millions testing a molecule as a drug, the law prevents the supplement industry from selling the same molecule over the counter and undercutting that investment.
A pharmaceutical company called Metro International Biotech had been running clinical trials on a proprietary form of NMN called MIB-626. The FDA determined that NMN had been authorized for drug investigation and, critically, that it had not been legitimately marketed as a supplement before that authorization. That second point was the linchpin: if NMN had been on the supplement market first, it would have been grandfathered in.
Amazon and Retailers Responded Quickly
Amazon moved fast. In early 2023, the platform began removing NMN supplements, telling sellers that NMN was “now considered a drug, or drug ingredient, that requires FDA approval” and that products containing it could no longer be sold as dietary supplements. Sellers had until March 13, 2023, to submit removal orders for their inventory. Amazon warned that any unsold stock left after 30 days would be disposed of.
Many smaller retailers followed suit or stopped restocking NMN. Some supplement brands reformulated products to replace NMN with nicotinamide riboside (NR), a related NAD+ precursor that wasn’t affected by the ruling. Others continued selling NMN through their own websites, operating in a gray area where FDA enforcement was uncertain.
How the Ban Was Overturned
The Natural Products Association (NPA), a major supplement industry trade group, fought the decision on multiple fronts: a formal citizen petition to the FDA, conversations with congressional offices, and ultimately a federal lawsuit. The core argument was that NMN had, in fact, been sold as a supplement in the U.S. before the drug investigation began.
The FDA eventually agreed. In its reversal, the agency concluded there was enough evidence that NMN had been marketed as a dietary supplement before it was authorized for drug investigation. Notably, the FDA clarified that it doesn’t require proof the earlier marketing was fully lawful or compliant with all regulations. It only requires evidence that the marketing occurred in the United States before the critical drug authorization date. In other words, the fact that NMN supplements existed on the market before the drug trials started was enough to qualify it under the “race to market” provision.
Following this response, the NPA voluntarily dismissed its lawsuit. Daniel Fabricant, the association’s president, called the reversal “a massive U-turn” and noted it required extraordinary investment from the industry, including formal litigation against the FDA.
Current Legal Status Around the World
In the United States, NMN is now classified as a dietary supplement ingredient. You can buy it online and in stores without restriction.
In the European Union, NMN is classified as a novel food, meaning it needs formal authorization before it can be legally sold in food supplements. An application has been submitted under EU novel food regulations requesting authorization for NMN as a food supplement ingredient at doses up to 500 mg per day. The application’s safety assessment concluded the product is safe for human health at the proposed use levels, but the authorization process is still ongoing.
In Canada, NMN appears in Health Canada’s Natural Health Products Ingredients Database, which serves as a guide for companies applying for product licenses to sell natural health products.
NMN Safety in Clinical Trials
The FDA’s decision to block NMN was never about safety. It was purely a legal classification issue. The clinical evidence on NMN’s safety profile is reassuring, if still limited in scale.
A 2024 systematic review of randomized controlled trials found that NMN dosages ranging from 150 to 1,200 mg per day produced no serious adverse effects. Across the studies reviewed, 36 out of 439 participants (about 8%) reported some kind of adverse event, but none were classified as severe. The reported events included things like brief abdominal pain after taking a dose, mild upper respiratory symptoms, loose stool, and occasional skin issues like acne or hives. In each case, researchers determined these events were unrelated to NMN supplementation, with all participants recovering fully.
This is a notably clean side effect profile compared to other NAD+ precursors. Nicotinamide and niacin, which are commonly used to treat high cholesterol, are associated with flushing, elevated blood sugar, increased liver enzymes, and gastrointestinal problems. Nicotinamide riboside has been linked to low platelet counts, diarrhea, nausea, and leg cramps. NMN has not shown these patterns in the trials conducted so far.
What This Means for Buyers
If you tried to buy NMN in 2023 or 2024 and found it unavailable or hard to source, that’s no longer the case. The supplement is back on major retail platforms and can be purchased without any legal issue in the United States. You don’t need a prescription, and there are no restrictions on personal possession or consumption.
The episode does highlight how quickly supplement availability can change based on regulatory decisions that have nothing to do with whether a product is safe or effective. NMN wasn’t pulled because it harmed anyone. It was pulled because a pharmaceutical company’s clinical trial triggered a legal clause designed to protect drug development investments. The supplement industry successfully argued the clause didn’t apply, and the FDA agreed.